Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that is representative of antiangiogenic drugs and has been approved for the treatment of GIST and renal cell carcinoma [51,52]. Here, NTRK1 is linked to hereditary clear cell renal cell carcinoma.